PIK3CA and ovarian cancer: The two mTOR/PI3K inhibitors, Gedatolisib (1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea) and PF-04691502 (2-Amino-8-[trans-4-(2-hydroxyethoxy) cyclohexyl]-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d] pyrimidin-7(8 H)-one), were first assessed against the HOX 552 ovarian cancer xenograft model.